Evidence map›Paper›PMID 40998733›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Preclinical Evaluation of [

Feifei Liu, Melissa E Monterosso, Didier Boucher, Stelle Shakti, Kwong Ching Li, Chanwoo Kim, Amber Prior, Abby Sydes, Amelia T Soderholm, Nicholas Fletcher and 13 more

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Feifei LiuAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Melissa E MonterossoAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Didier BoucherAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Stelle ShaktiAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Kwong Ching LiAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Chanwoo KimAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Amber PriorAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Abby SydesAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Amelia T SoderholmAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Nicholas FletcherCentre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Dewan AkhterCentre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
Kristofer ThurechtCentre for Advanced Imaging and Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
William TieuAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Kevin KuanAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Aimee HorsfallAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Saawan KumarAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Johannes KoehbachAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Edward HammondAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Anna KarmannAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Stephen RoseAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Gary LiAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and thomas.kryza@advancell.com.au gary.li@advancell.com.au.
Simon PuttickAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and.
Thomas KryzaAdvanCell Pty Ltd., Sydney, New South Wales, Australia; and thomas.kryza@advancell.com.au gary.li@advancell.com.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA)-directed radiopharmaceutical therapies continue to improve treatment outcomes in patients with metastatic castration-resistant prostate cancer. Here, we report the in vitro and in vivo characterization of a PSMA-targeted therapy (ADVC001) specifically designed for targeted α-therapy with

Indexed as

Alpha ParticlesAntigens, SurfaceGlutamate Carboxypeptidase IILead RadioisotopesMolecular Targeted TherapyProstatic NeoplasmsAnimalsCell Line, TumorDrug Evaluation, PreclinicalHumansMaleMiceRadiopharmaceuticalsTissue DistributionXenograft Model Antitumor AssaysAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IILead-212Lead RadioisotopesRadiopharmaceuticals212Pbpreclinicalprostate cancerPSMAtargeted α-therapytheranostics

Identifiers

PMID40998733
PMCPMC12582184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.